# A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Source: https://onco.cc/trials/nct06860971/  
OnCo record `nct06860971` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing AL2846 in thyroid cancer, now recruiting.

## Summary

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma is a phase 3 interventional study registered as NCT06860971, led by Chia Tai Tianqing Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy. Planned enrolment is 144 participants (estimated). The study started in 2025-04-18 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06860971
- Phase: 3
- Setting: A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy
- Sponsor: Chia Tai Tianqing Pharmaceutical
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT06860971: https://clinicaltrials.gov/study/NCT06860971

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- drugs: [AL2846](https://onco.cc/drugs/al2846/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06860971.json